Compared to the vehicle and Y332D monotherapy, the RT plus Y332D therapy significantly increased the tumor‐infiltrating abundance of lymphocytes, CD3+ T, CD8+ T, activated CD8+ T (CD25+/CD69+ CD8+), cytotoxic CD8+ T (Gzmb+ CD8+ T and IFN‐γ+ CD8+ T), and proliferating CD8+ T (Ki67+ CD8+ T) cells (Figure 6e,g). This evidence concerns the gene CD8A and neoplasm.